CV Therapeutics Angina Drug Not Effective in Study; Shares Plunge

Shares of CV Therapeutics plummeted following the company's announcement late Tuesday that its angina drug ranolazine was not effective in a study of acute and long-term treatment of patients with a type of heart disease known as acute coronary syndrome.

Wednesday's drop came on top of the shares losing more than a quarter of their value in after-market trading Tuesday.

There was no adverse trend in death or arrhythmias in patients taking the drug, also known by the chemical name ranolazine, the company said.

CV Therapeutics said it believes the data could support expansion of the drug's approved uses to be included as a first choice treatment for angina. It is currently approved to treat chronic angina in patients who have not achieved an adequate response with other drugs.

Contact U.S. News


    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video

  • CNBC's Jackie DeAngelis reports gold has hit its lowest level since June, and crude oil dropped $3.08, closing at $92.88 a barrel as traders say geopolitics appears manageable driving prices lower.

  • Discussing the short-term decline in energy prices and how it impacts the equity market, with Lindsey Piegza, Sterne Agee; Hugh Anderson, HighTower; Hank Smith, Haverford Investments; and CNBC's Rick Santelli.

  • Brian Boyle, Boyle Capital president, sees huge opportunity at AIG. Barry James, James Advantage Funds, shares his top stock picks.